摘要
目的比较阿立哌唑和奋乃静对首发精神分裂症认知功能的影响。方法将符合入组标准的首发男性精神分裂症患者60例随机分为阿立哌唑组与奋乃静组,分别进行6周的系统治疗,采用简明精神病评定量表(BPRS)、简易智能状态检查量表(MMSE)进行测评其疗效和对认知功能的影响。结果 60例患者在6周治疗后BPRS总分明显下降(P<0.01),但2组之间的差异无统计学意义(P>0.05)。阿立哌唑组的MMSE总分明显高于奋乃静组,差异有统计学意义(P<0.05)。结论阿立哌唑组对首发男性精神分裂症认知功能的影响明显好于奋乃静组。
Objective To compare the effects of aripiprazole and perphenazine on cognitive function in the first-onset male schizo-phrenic patient. Methods 60 patients with first-onset male schizophrenia were randomly divided into aripiprazole group and per-phenazine group for 6 weeks. The therapeutic response and cognitive function were assessed by the Brief Psychiatric Rating Scale ( BPRS) ,and Mini-Mental State Examination( MMSE). Results The total score of BPRS was significantly decreased after the treat-ment with aripiprazole and perphenazine( P〈0.01 ), but no significant difference was found between the two groups ( P〉0.05 ). The total score of MMSE was significantly higher than that the aripiprazole group and the perphenazine group(P〈0.05 ). Conclu-sions The study suggests that the effects of aripiprazole on cognitive function in first-onset male schizophrenia be better than that of perphenazine.
出处
《西北药学杂志》
CAS
2012年第5期471-472,共2页
Northwest Pharmaceutical Journal